Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Cash from Investing Activities (2022 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Cash from Investing Activities for 4 consecutive years, with -$98847.0 as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities rose 99.74% to -$98847.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2025, up 105.55% year-over-year, with the annual reading at $2.1 million for FY2025, 105.55% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$98847.0 at Inhibikase Therapeutics, up from -$28.7 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $21.1 million in Q1 2025, with the low at -$38.8 million in Q4 2024.
  • Average Cash from Investing Activities over 4 years is -$2.6 million, with a median of -$43089.0 recorded in 2022.
  • The sharpest move saw Cash from Investing Activities surged 6017.7% in 2023, then tumbled 1732.19% in 2024.
  • Over 4 years, Cash from Investing Activities stood at $5.0 million in 2022, then plummeted by 142.63% to -$2.1 million in 2023, then crashed by 1732.19% to -$38.8 million in 2024, then soared by 99.74% to -$98847.0 in 2025.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at -$98847.0, -$28.7 million, and $9.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.